Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | GLA | P06280 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | S100A4 | P26447 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17987 | 1.00 | ALDH1A1 (0.48) | ALDH1A1KDM4ESMN1; SMN2MAPTGAA | |
| SCHEMBL29362920 | 1.00 | ALDH1A1 (0.48) | ALDH1A1KDM4ESMN1; SMN2MAPTGAA | |
| SCHEMBL4921603 | 0.96 | ALDH1A1 (0.46) | ALDH1A1KDM4ESMN1; SMN2MAPTGAA | |
| SCHEMBL30139899 | 0.96 | ALDH1A1 (0.46) | ALDH1A1KDM4ESMN1; SMN2MAPTGAA | |
| Water SCHEMBL1512563 | 0.96 | ALDH1A1 (0.46) | ALDH1A1KDM4ESMN1; SMN2MAPTGAA | |
| SCHEMBL5536637 | 0.96 | ALDH1A1 (0.46) | ALDH1A1KDM4ESMN1; SMN2MAPTGAA | |
| Water SCHEMBL592692 | 0.96 | ALDH1A1 (0.46) | ALDH1A1KDM4ESMN1; SMN2MAPTGAA | |
| Water SCHEMBL29662270 | 0.96 | ALDH1A1 (0.46) | ALDH1A1KDM4ESMN1; SMN2MAPTGAA | |
| SCHEMBL4930798 | 0.96 | ALDH1A1 (0.46) | ALDH1A1KDM4ESMN1; SMN2MAPTGAA | |
| Water SCHEMBL28087086 | 0.96 | ALDH1A1 (0.46) | ALDH1A1KDM4ESMN1; SMN2MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110628476-B | Pretreatment method and purifying agent for refinery rich gas and desulfurization method for dry gas and/or liquefied gas | 中国石油化工股份有限公司 | 2020-11-13 | — | — | CN | claimed |
| CN-110628476-A | Pretreatment method and purifying agent for refinery rich gas and desulfurization method for dry gas and/or liquefied gas | 中国石油化工股份有限公司 | 2019-12-31 | — | — | CN | claimed |
| US-9717699-B2 | Sterilized compositions of cyanoacrylate monomers and naphthoquinone 2,3-oxides | ADHEZION BIOMEDICAL, LLC (US) | 2017-08-01 | — | — | US | claimed |
| US-20160331700-A1 | Sterilized Compositions of Cyanoacrylate Monomers and Naphthoquinone 2,3-Oxides | H.B. FULLER MEDICAL ADHESIVE TECHNOLOGIES, LLC. | 2016-11-17 | — | — | US | claimed |
| US-20150283290-A1 | STERILIZED COMPOSITIONS OF CYANOACRYLATE MONOMERS AND NAPHTHOQUINONE 2,3-OXIDES | ADHEZION BIOMEDICAL, LLC (US) | 2015-10-08 | — | — | US | claimed |
| EP-1525001-A1 | CONJUGATES OF PORPHYRIN COMPOUNDS WITH CHEMOTHERAPEUTIC AGENTS | Cellgate Inc. (US) | 2005-04-27 | — | — | EP | claimed |
| US-20040192665-A1 | Conjugates of porphyrin compounds with chemotherapeutic agents | SLIL BIOMEDICAL CORPORATION | 2004-09-30 | — | — | US | claimed |
| WO-2004012774-A1 | CONJUGATES OF PORPHYRIN COMPOUNDS WITH CHEMOTHERAPEUTIC AGENTS | CELLGATE, INC. (US) | 2004-02-12 | — | — | WO | claimed |
| EP-0759040-B1 | CARBONYL CONTAINING COMPOUNDS AND THEIR DERIVATIVES AS MULTI-FUNCTIONAL FUEL AND LUBE ADDITIVES | EXXON RESEARCH ENGINEERING CO (US) | 1999-01-27 | — | — | EP | claimed |
| CN-117062636-A | Catheter securement compositions and methods | 艾德合森生物医药有限责任公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20230302144-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | ONCOSELECT THERAPEUTICS, LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-11590233-B2 | Porphyrin compounds and compositions useful for treating cancer | ONCOSELECT THERAPEUTICS, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| CN-109922834-B | Porphyrin compounds and compositions for the treatment of cancer | 良药治疗公司 | 2022-09-23 | — | — | CN | disclosed |
| US-20220218951-A1 | CATHETER SECUREMENT COMPOSITIONS AND METHODS PROVIDING SIGNIFICANTLY STRONG SECUREMENT, WATER RESISTANT SEAL, EFFECTIVE HEMOSTATIS, AND ANTIBACTERIAL PROPERTIES AT AND AROUND VASCULAR ACCESS SITES | H.B. FULLER MEDICAL ADHESIVE TECHNOLOGIES, LLC. | 2022-07-14 | — | — | US | disclosed |
| EP-0759040-A1 | CARBONYL CONTAINING COMPOUNDS AND THEIR DERIVATIVES AS MULTI-FUNCTIONAL FUEL AND LUBE ADDITIVES | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1997-02-26 | — | — | EP | disclosed |
| WO-1995031488-A1 | CARBONYL CONTAINING COMPOUNDS AND THEIR DERIVATIVES AS MULTI-FUNCTIONAL FUEL AND LUBE ADDITIVES | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1995-11-23 | — | — | WO | disclosed |
| US-5314914-A | Methods and compositions for combatting herpes viruses | BIOMEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-05-24 | — | — | US | disclosed |
| US-5242946-A | Treating herpes Viral infections | BIO-MEGA, INC. (CA) | 1993-09-07 | — | — | US | disclosed |
| US-4216078-A | Hydrogenation of petroleum liquids using quinone catalysts | EXXON RESEARCH & ENGINEERING CO. (US) | 1980-08-05 | — | — | US | disclosed |
| US-4049537-A | SLURRYING COAL, SOLVENT, AND A QUINONE, CONTACTING WITH HYDROGEN | EXXON RESEARCH & ENGINEERING CO. (US) | 1977-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192665-A1 | Conjugates of porphyrin compounds with chemotherapeutic agents | PPOX, PPIF, HMBS | ALDH1A1 1866/4885KDM4E 2831/4885SMN1; SMN2 1882/4885 |
| US-20230302144-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | KIT, HCCS, PPIF | ALDH1A1 2847/4885KDM4E 2828/4885SMN1; SMN2 2987/4885 |
| US-11590233-B2 | Porphyrin compounds and compositions useful for treating cancer | KIT, HCCS, PPIF | ALDH1A1 2847/4885KDM4E 2828/4885SMN1; SMN2 2987/4885 |
| US-20160331700-A1 | Sterilized Compositions of Cyanoacrylate Monomers and Naphthoquinone 2,3-Oxides | PROC, CCNK, MMS19 | ALDH1A1 1806/4885KDM4E 1898/4885SMN1; SMN2 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.